AKT1 and breast cancer: Activation of PI3KCA-AKT-mTOR pathway is known as the most important and prevalent mechanism of endocrine resistance in BC, as clinical trials have confirmed the definite efficacy of drugs targeting PI3KCA, AKT or mTOR [5–7].